Topic:Vaccine development
Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals. Single-radial-immunodiffusion (SRD) provides a sensitive and reproducible in vitro assay for haemagglutinin (HA) concentration in inactivated influenza vaccines. The use of SRD for human influenza vaccine standardization and application for equine and avian influenza vaccines is discussed. In clinical trials, vaccine HA concentration measured by SRD has been shown to be directly related to antibody responses and to protection against challenge. The use of SRD may considerably reduce the usage of animals for potency testing of veterinary influenza vaccines.
[Creation of an avirulent and immunogenic mutant from the rhinopneumonitis virus]. An avirulent immunogenic virus strain mutant of the causative agent of rhinopneumonia was found to cause abortions and respiratory diseases in horses. The mutant was obtained with the use of a virulent strain that induced strongly manifested clinical symptoms of the disease, and was cultured in cell media containing 5-iodine-2-desoxiuridine as an antimetabolite, following a definite pattern. It was found that the mutant completely lost its virulence, however, it retained its immunogenicity. It likewise retained these newly acquired biologic properties with regard to its being stable and irreve...
Studies on the immunogenicity of Streptococcus equi vaccines in foals. The ability of either formalin-treated or heat-inactivated whole Streptococcus equi cell vaccines or partially purified M-protein of S. equi to give rise to protective antibody levels was studied in Standardbred foals by serological means. Two commercial preparations, i.e. a beta-propiolactone killed whole S. equi cell bacterin and a cell-free extract of S. equi cells were included in the study. The mean passive hemagglutination antibody titers (10 X log2) in sera of foals given either four doses of formalin-treated whole cell vaccine or an initial dose of formalin-treated followed by three do...
Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus). The specificity of selected immune responses to equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4) was examined in 3 colostrum-deprived specific-pathogen-free foals. Single foals were vaccinated with inactivated EHV-1, inactivated EHV-4, or control cell lysate plus adjuvant followed by successive intranasal challenge exposures with EHV-1 and EHV-4 or with EHV-4 and EHV-1. Vaccination with inactivated virus preparations elicited cellular immune responses and antibody which were augmented by subsequent challenge exposures. Cellular immune responses, as measured by in vitro lymphocyte blastogen...
Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 1 virus. Vaccinated yearlings , two-year-old and in-foal pony mares with appropriate controls were exposed to aerosols of a subtype 1 virus one to two months after two or three vaccinations; all became infected. No obvious differences in the febrile responses, clinical signs and subsequent abortions were found between vaccinated and control mares. All vaccinated yearlings and two-year-old ponies developed a febrile respiratory disease but this was less severe than that suffered by the controls and the amounts and duration of virus shedding were reduced.
Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 2 virus. Serological responses following two and three doses of an inactivated equid herpesvirus 1 ( EHV -1) vaccine containing a subtype 1 strain were examined in yearling ponies. Complement fixing antibody responses were significantly higher against the subtype 1 vaccine strain than against a subtype 2 virus. Complement fixing antibody responses declined rapidly after the second dose of vaccine and had returned to almost pre-vaccination levels eight weeks after the second dose of vaccine. Complement fixing antibody titres to the heterologous subtype 2 strain increased after each successive dose of va...
Equine immunology 4: vaccines and antisera. This paper attempts to relate the practicalities of vaccine development to the ideals which should be aimed for in a new vaccine. The type of immune response induced is dependent upon the nature of the antigen in the vaccine and the site and timing of its presentation to the immune system. In this respect the influence of age, maternal immunity and antigenic competition are discussed. The possible side effects associated with vaccination are defined and vaccines which are currently available for horses are reviewed. These vaccines are mostly for the prevention of respiratory disease. Finally, ...
Studies with inactivated equine influenza vaccine. 1. Serological responses of ponies to graded doses of vaccine. Serological responses to three bivalent aqueous equine influenza vaccines of different potency and an adjuvanted bivalent vaccine containing inactivated A/equine/Prague/56 (H7N7) and A/equine/Miami/63 (H3N8) viruses, were examined in seronegative ponies. Potencies of the vaccines, measured by single-radial-diffusion tests, ranged from 4 to 56 micrograms of haemagglutinin (HA) antigen activity/virus strain per dose. Serological responses to vaccination were examined by haemagglutination-inhibition (HI) and single-radial-haemolysis (SRH) tests. Four weeks after a primary dose, HI responses to bo...
Studies with inactivated equine influenza vaccine. 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8). Forty ponies immunized with inactivated virus vaccine containing A/equine/Miami/63 (H3N8) virus and six unvaccinated, seronegative ponies were experimentally challenged with a representative of recent equine H3N8 virus isolates, A/equine/Newmarket/79. All unvaccinated ponies became infected as judged by virus excretion, febrile responses and antibody responses, but only two of the vaccinated ponies were fully protected. Pre-challenge antibody levels to A/Newmarket/79 virus detected by single radial haemolysis (SRH) correlated well with the degree of clinical protection but the levels required ...
Analysis of antigenic variation in equine 2 influenza A viruses. Influenza outbreaks involving viruses of the H3N8 subtype (equine 2) often occur in vaccinated horses. For this reason, a series of influenza viruses of the H3N8 subtype were examined to determine if antigenic variation could be detected in isolates during the period 1963-81. Antigenic analyses with post-infection ferret sera and monoclonal antibodies showed that the haemagglutinins of recent isolates were antigenically distinguishable from the prototype A/eq/Miami/1/63 and that antigenically distinguishable groups of equine 2 viruses co-circulate in the horse population. Based on these studie...
Venezuelan equine encephalomyelitis virus: concentration, partial purification, inactivation and immunogenicity. Venezuelan equine encephalomyelitis (VEE) TC-84 vaccinal virus, from 10-1. quantities of infected duck embryo fibroblast cell culture fluids, was isolated by combined continuous-flow centrifugation with isopycnic banding in sucrose. Most of the recovered infectivity and hemagglutinating activity were in a single band at a buoyant density (rho) of 1.2. About 90% of the total input protein (450-520 mg) was removed with the effluent, whereas most of the remaining 10% also banded at a rho of 1.2. Infectivity was inactivated with formalin at a final concentration of 0.05% at 37 degrees C for 24 hr....
Immunogenicity of equine herpesvirus type 1 (EHV1) and equine rhinovirus type 1 (ERhV1) following inactivation by betapropiolactone (BPL) and ultraviolet (UV) light. Some kinetic data on the inactivation of equine herpesvirus type 1 (EHV1) and equine rhinovirus type 1 (ERhV1) by betapropiolactone (BPL) and ultraviolet (UV) irradiation are reported. 0.25% BPL at 37 degrees C for 1 h reduced the titre of EHV1 by greater than 10(3 . 4) and of ERhV1 by greater than 10(4 . 1) TCID50/ml. UV irradiation (334 microW/cm2) produced similar reductions in titre after 2 min. These data were used as a basis for inactivating EHV1 and ERhV1 by the combined action of BPL and UV irradiation. Viruses were exposed to 0.1% BPL for 1 h at 4 degrees C with constant stirring, fol...
Respiratory tract immune response to microbial pathogens. Effective resistance to respiratory tract infection depends principally on specific immunity on mucosal surfaces of the upper or lower respiratory tract. Respiratory tract immune response comprises antibody and cell-mediated systems and may be induced most readily by surface presentation of replicating agents but can result from parenteral or local presentation of highly immunogenic antigens. Upper and lower respiratory tract systems differ in immunologic competence, with the lungs having a greater inventory of protective mechanisms than the trachea or nose. Several effective vaccines have bee...
Enhancement of Naja naja atra antivenin production in horses. As the conventional hyperimmunization schedule in horses introduced by Tanaka could not produce enough neutralizing antibody against Naja naja atra venom, the mixture of Carboxymethyl cellulose (CMC)-Cobra venom incorporated with adjuvant was used for immunization. The neutralizing antibody produced (30 LD50) seemed to be increased but still not to reach the satisfactory level. By using CMC-Cobratoxin adjuvant mixture as an immunizing agent, highly potent antivenin (220 LD50) was obtained.
Application of a chemically inactivated, adjuvanted vaccine to control abortigenic infection of mares by equine herpesvirus I. A chemically inactivated, adjuvanted vaccine prepared from a virulent strain of Equine herpesvirus I (EHV-I) was used to immunize pregnant Thoroughbred broodmares during a five-year field test designed to determine its safety and efficacy. Each mare in the vaccinated groups received 3 intramuscular injections of vaccine beginning immediately prior to and during the last half of pregnancy. Vaccine was injected at approximately 60-day intervals. The accumulated incidence of EHV-I abortions among vaccinated mares during the field trial period was 1.6/1000 as compared with an incidence of 6.8/1000...
Antigenic properties of some equine influenza viruses. The antigenic relationships between the haemagglutinins of five A/equine-1 viruses and between six A/equine-2 viruses were examined using post-infection ferret and immunized pony sera. Similar results were obtained with sera from both species for the A/equine-1 viruses and these confirmed minor antigenic differences between the prototype A/Prague 1/56 virus and viruses isolated in England in 1973 and 1977. Considerable antigenic differences were found between five of the A/equine-2 viruses, using ferret sera, but these differences were less evident using pony sera. The response of ponies to th...
A summary of antibody titration experiments in some animal species treated with ERA vaccine and an inactivated rabies vaccine. The results of antibody titrations in different animal species vaccinated against rabies are reported. The following points are considered: (1) antibody titration may be used to detect an immunity status in dogs, (2) equines should be vaccinated in infected areas, (3) experiments in progress are comparing ERA vaccine and an inactivated vaccine in bovines, and (4) the vaccination of fallow deer (Dama dama) and moufflons (Ovis ammon musimon) produced results suggesting an extension of the experiment with the purpose of vaccinating wild ruminants whenever possible.
Mechanisms of infection in the respiratory tract. Related to its potential vulnerability the respiratory tract has a very complex and effective defence apparatus. The interaction between these defence mechanisms and certain characteristics of aetiological agents results in a pattern in which initial infections by these agents tend to occur at specific sites in the tract. Infections in which the primary portal of entry is in the upper respiratory tract include Bordetella bronchiseptica and Haemophilus spp in pigs; Pasteurella spp in cattle, sheep, pigs; Mycoplasma spp in cattle, sheep, pigs and poultry; equine herpesvirus 1 in horses; infectio...